SK&F Velocity Agreement
Executive Summary
SK&F reached interim agreement with the Velocity Hospital Group during the week of May 21-25 in relation to Northwestern Drug (Wash.) private antitrust suit v. SK&F and four other mfrs. SK&F will provide normal chargeback allowance on products purchased by Velocity Group plus up to 3% of whsle. price to compensate Velocity Group for extra costs of having to search for alternative supplier. If SK&F prevails in the suit, reimbursement for extra costs will be returned by hospitals to the mfr. Velocity group had claimed it would be put out of business by mfrs. refusal to do business with Northwestern.
You may also be interested in...
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: